{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:25:35Z","timestamp":1788884735808,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016834","name":"Chongqing Municipal Health Commission","doi-asserted-by":"crossref","award":["CQYC2020020331"],"award-info":[{"award-number":["CQYC2020020331"]}],"id":[{"id":"10.13039\/100016834","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chongqing Municipal Bureau of Science and Technology","award":["cstc2021ycjh-bgzxm0050"],"award-info":[{"award-number":["cstc2021ycjh-bgzxm0050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biogerontology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10522-024-10093-y","type":"journal-article","created":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T23:12:21Z","timestamp":1708902741000},"page":"567-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male\u00a0mice through the AMPK\u03b1\/MMP9\/TGF-\u03b21\/Smad pathway"],"prefix":"10.1007","volume":"25","author":[{"given":"Qixuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangchuan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"10093_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/nutrit\/nuac062","volume":"81","author":"AA Aragon","year":"2023","unstructured":"Aragon AA, Tipton KD, Schoenfeld BJ (2023) Age-related muscle anabolic resistance: inevitable or preventable? Nutr Rev 81:441\u2013454. https:\/\/doi.org\/10.1093\/nutrit\/nuac062","journal-title":"Nutr Rev"},{"key":"10093_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.7150\/ijbs.4262","volume":"8","author":"ST Arthur","year":"2012","unstructured":"Arthur ST, Cooley ID (2012) The effect of physiological stimuli on sarcopenia; impact of Notch and Wnt signaling on impaired aged skeletal muscle repair. Int J Biol Sci 8:731\u2013760. https:\/\/doi.org\/10.7150\/ijbs.4262","journal-title":"Int J Biol Sci"},{"key":"10093_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.1144090","volume":"317","author":"AS Brack","year":"2007","unstructured":"Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA (2007) Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 317:807\u2013810","journal-title":"Science"},{"key":"10093_CR4","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/j.redox.2022.102288","volume":"52","author":"C Cai","year":"2022","unstructured":"Cai C, Guo Z, Chang X, Li Z, Wu F, He J, Cao T, Wang K, Shi N, Zhou H, Toan S, Muid D, Tan Y (2022) Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol 52:102288. https:\/\/doi.org\/10.1016\/j.redox.2022.102288","journal-title":"Redox Biol"},{"key":"10093_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","volume":"21","author":"S Chen","year":"2022","unstructured":"Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ (2022) Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol 21:45. https:\/\/doi.org\/10.1186\/s12933-022-01480-1","journal-title":"Cardiovasc Diabetol"},{"key":"10093_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Sayer AA (2019) Sarcopenia. Lancet 393:2636\u20132646. https:\/\/doi.org\/10.1016\/S0140-6736(19)31138-9","journal-title":"Lancet"},{"key":"10093_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA Defronzo","year":"2017","unstructured":"Defronzo RA, Norton L, Abdul-Ghani M (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13:11\u201326. https:\/\/doi.org\/10.1038\/nrneph.2016.170","journal-title":"Nat Rev Nephrol"},{"key":"10093_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119481","author":"HE-S El-Horany","year":"2023","unstructured":"El-Horany HE-S, Atef MM, Abdel Ghafar MT, Fouda MH, Nasef NA, Hegab II, Helal DS, Elseady W, Hafez YM, Hagag RY, Seleem MA, Saleh MM, Radwan DA, Abd El-Lateef AE, Abd-Ellatif RN (2023) Empagliflozin ameliorates bleomycin-induced pulmonary fibrosis in rats by modulating Sesn2\/AMPK\/Nrf2 signaling and targeting ferroptosis and autophagy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24119481","journal-title":"Int J Mol Sci"},{"key":"10093_CR9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial. Eur Heart J 37:1526\u20131534. https:\/\/doi.org\/10.1093\/eurheartj\/ehv728","journal-title":"Eur Heart J"},{"key":"10093_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1 (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10:393\u2013406. https:\/\/doi.org\/10.1016\/S2213-8587(22)00070-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10093_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ (2018) AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol 19:121\u2013135. https:\/\/doi.org\/10.1038\/nrm.2017.95","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10093_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cytogfr.2011.06.002","volume":"22","author":"CE Hills","year":"2011","unstructured":"Hills CE, Squires PE (2011) The role of TGF-\u03b2 and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 22:131\u2013139. https:\/\/doi.org\/10.1016\/j.cytogfr.2011.06.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10093_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/1573399816666200705210006","volume":"17","author":"S Ida","year":"2021","unstructured":"Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, Fujiwara R, Murata K (2021) Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Curr Diabetes Rev 17:293\u2013303. https:\/\/doi.org\/10.2174\/1573399816666200705210006","journal-title":"Curr Diabetes Rev"},{"key":"10093_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","volume":"36","author":"S Kang","year":"2020","unstructured":"Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, Guzzardi DG, Svystonyuk DA, Pattar SS, Park DSJ, Turnbull JD, Duff HJ, Tibbles LA, Cunnington RH, Dyck JRB, Fedak PWM (2020) Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol 36:543\u2013553. https:\/\/doi.org\/10.1016\/j.cjca.2019.08.033","journal-title":"Can J Cardiol"},{"key":"10093_CR15","doi-asserted-by":"publisher","first-page":"104870","DOI":"10.1016\/j.phrs.2020.104870","volume":"158","author":"CN Koyani","year":"2020","unstructured":"Koyani CN, Plastira I, Sourij H, Hallstr\u00f6m S, Schmidt A, Rainer PP, Bugger H, Frank S, Malle E, Von Lewinski D (2020) Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res 158:104870. https:\/\/doi.org\/10.1016\/j.phrs.2020.104870","journal-title":"Pharmacol Res"},{"key":"10093_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.7150\/ijbs.7.1056","volume":"7","author":"HY Lan","year":"2011","unstructured":"Lan HY (2011) Diverse roles of TGF-\u03b2\/Smads in renal fibrosis and inflammation. Int J Biol Sci 7:1056\u20131067","journal-title":"Int J Biol Sci"},{"key":"10093_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, Yu X, Sun B, Chen L (2019) SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 18:15. https:\/\/doi.org\/10.1186\/s12933-019-0816-2","journal-title":"Cardiovasc Diabetol"},{"key":"10093_CR18","doi-asserted-by":"publisher","first-page":"589273","DOI":"10.3389\/fphar.2021.589273","volume":"12","author":"L Li","year":"2021","unstructured":"Li L, Li Q, Huang W, Han Y, Tan H, An M, Xiang Q, Zhou R, Yang L, Cheng Y (2021) Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol 12:589273. https:\/\/doi.org\/10.3389\/fphar.2021.589273","journal-title":"Front Pharmacol"},{"key":"10093_CR19","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","volume":"43","author":"K Lin","year":"2022","unstructured":"Lin K, Yang N, Luo W, Qian J-F, Zhu W-W, Ye S-J, Yuan C-X, Xu D-Y, Liang G, Huang W-J, Shan P-R (2022) Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling. Acta Pharmacol Sin 43:2624\u20132635. https:\/\/doi.org\/10.1038\/s41401-022-00885-8","journal-title":"Acta Pharmacol Sin"},{"key":"10093_CR20","doi-asserted-by":"publisher","first-page":"154334","DOI":"10.1016\/j.metabol.2020.154334","volume":"111","author":"X Liu","year":"2020","unstructured":"Liu X, Xu C, Xu L, Li X, Sun H, Xue M, Li T, Yu X, Sun B, Chen L (2020) Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK\/SP1\/PGAM5 pathway. Metabolism 111:154334. https:\/\/doi.org\/10.1016\/j.metabol.2020.154334","journal-title":"Metabolism"},{"key":"10093_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/jcsm.13150","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Zhao L, Gao Y, Chen Y, Tian Q, Son JS, Chae SA, De Avila JM, Zhu M-J, Du M (2023) AMP-activated protein kinase inhibition in fibro-adipogenic progenitors impairs muscle regeneration and increases fibrosis. J Cachexia Sarcopenia Muscle 14:479\u2013492. https:\/\/doi.org\/10.1002\/jcsm.13150","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10093_CR22","doi-asserted-by":"publisher","first-page":"113947","DOI":"10.1016\/j.biopha.2022.113947","volume":"156","author":"Y-P Lu","year":"2022","unstructured":"Lu Y-P, Wu H-W, Zhu T, Li X-T, Zuo J, Hasan AA, Reichetzeder C, Delic D, Yard B, Klein T, Kr\u00e4mer BK, Zhang Z-Y, Wang X-H, Yin L-H, Dai Y, Zheng Z-H, Hocher B (2022) Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5\/6-nephrectomy. Biomed Pharmacother 156:113947. https:\/\/doi.org\/10.1016\/j.biopha.2022.113947","journal-title":"Biomed Pharmacother"},{"key":"10093_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.exger.2019.04.008","volume":"122","author":"A-K Lyu","year":"2019","unstructured":"Lyu A-K, Zhu S-Y, Chen J-L, Zhao Y-X, Pu D, Luo C, Lyu Q, Fan Z, Sun Y, Wu J, Zhao K-X, Xiao Q (2019) Inhibition of TLR9 attenuates skeletal muscle fibrosis in aged sarcopenic mice via the p53\/SIRT1 pathway. Exp Gerontol 122:25\u201333. https:\/\/doi.org\/10.1016\/j.exger.2019.04.008","journal-title":"Exp Gerontol"},{"key":"10093_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"X-M Meng","year":"2016","unstructured":"Meng X-M, Nikolic-Paterson DJ, Lan HY (2016) TGF-\u03b2: the master regulator of fibrosis. Nat Rev Nephrol 12:325\u2013338. https:\/\/doi.org\/10.1038\/nrneph.2016.48","journal-title":"Nat Rev Nephrol"},{"key":"10093_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tem.2022.03.005","volume":"33","author":"JS Moon","year":"2022","unstructured":"Moon JS, Hong JH, Jung YJ, Ferrannini E, Nauck MA, Lim S (2022) SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 33:424\u2013442. https:\/\/doi.org\/10.1016\/j.tem.2022.03.005","journal-title":"Trends Endocrinol Metab"},{"key":"10093_CR26","doi-asserted-by":"publisher","first-page":"107212","DOI":"10.1016\/j.vph.2023.107212","volume":"152","author":"CHG Neutel","year":"2023","unstructured":"Neutel CHG, Wesley CD, Van Praet M, Civati C, Roth L, De Meyer GRY, Martinet W, Guns P-J (2023) Empagliflozin decreases ageing-associated arterial stiffening and vascular fibrosis under normoglycemic conditions. Vascul Pharmacol 152:107212. https:\/\/doi.org\/10.1016\/j.vph.2023.107212","journal-title":"Vascul Pharmacol"},{"key":"10093_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M, Canale ML, Botti G, Maurea N (2021) The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol 20:150. https:\/\/doi.org\/10.1186\/s12933-021-01346-y","journal-title":"Cardiovasc Diabetol"},{"key":"10093_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/07853890.2016.1226514","volume":"49","author":"D Raheli\u0107","year":"2017","unstructured":"Raheli\u0107 D, Javor E, Lucijani\u0107 T, Skelin M (2017) Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. Ann Med 49:51\u201362. https:\/\/doi.org\/10.1080\/07853890.2016.1226514","journal-title":"Ann Med"},{"key":"10093_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10522-008-9131-0","volume":"9","author":"JG Ryall","year":"2008","unstructured":"Ryall JG, Schertzer JD, Lynch GS (2008) Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology 9:213\u2013228. https:\/\/doi.org\/10.1007\/s10522-008-9131-0","journal-title":"Biogerontology"},{"key":"10093_CR30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ (2019) Empagliflozin ameliorates adverse left\u00a0ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol 73:1931\u20131944. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056","journal-title":"J Am Coll Cardiol"},{"key":"10093_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","volume":"14","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S, Picatoste B, Vargas-Delgado AP, Flores-Umanzor EJ, Sanz J, Fuster V, Badimon JJ (2021) Empagliflozin Ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart\u00a0failure: a multimodality study. JACC Cardiovasc Imaging 14:393\u2013407. https:\/\/doi.org\/10.1016\/j.jcmg.2020.07.042","journal-title":"JACC Cardiovasc Imaging"},{"key":"10093_CR32","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/jcsm.12560","volume":"11","author":"G-K Shang","year":"2020","unstructured":"Shang G-K, Han L, Wang Z-H, Liu Y-P, Yan S-B, Sai W-W, Wang D, Li Y-H, Zhang W, Zhong M (2020) Sarcopenia is attenuated by TRB3 knockout in aging mice via the alleviation of atrophy and fibrosis of skeletal muscles. J Cachexia Sarcopenia Muscle 11:1104\u20131120. https:\/\/doi.org\/10.1002\/jcsm.12560","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10093_CR33","doi-asserted-by":"publisher","first-page":"155657","DOI":"10.1016\/j.metabol.2023.155657","volume":"146","author":"Y Shen","year":"2023","unstructured":"Shen Y, Cheng L, Xu M, Wang W, Wan Z, Xiong H, Guo W, Cai M, Xu F (2023) SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis. Metabolism 146:155657. https:\/\/doi.org\/10.1016\/j.metabol.2023.155657","journal-title":"Metabolism"},{"key":"10093_CR34","doi-asserted-by":"publisher","first-page":"107374","DOI":"10.1016\/j.intimp.2021.107374","volume":"93","author":"Y Shentu","year":"2021","unstructured":"Shentu Y, Li Y, Xie S, Jiang H, Sun S, Lin R, Chen C, Bai Y, Zhang Y, Zheng C, Zhou Y (2021) Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-\u03b2\/Smad signaling. Int Immunopharmacol 93:107374. https:\/\/doi.org\/10.1016\/j.intimp.2021.107374","journal-title":"Int Immunopharmacol"},{"key":"10093_CR35","doi-asserted-by":"publisher","first-page":"121894","DOI":"10.1016\/j.lfs.2023.121894","volume":"329","author":"S Siapoush","year":"2023","unstructured":"Siapoush S, Rezaei R, Alavifard H, Hatami B, Zali MR, Vosough M, Lorzadeh S, \u0141os MJ, Baghaei K, Ghavami S (2023) Therapeutic implications of targeting autophagy and TGF-\u03b2 crosstalk for the treatment of liver fibrosis. Life Sci 329:121894. https:\/\/doi.org\/10.1016\/j.lfs.2023.121894","journal-title":"Life Sci"},{"key":"10093_CR36","doi-asserted-by":"publisher","first-page":"7642","DOI":"10.1111\/jcmm.16601","volume":"25","author":"J Tian","year":"2021","unstructured":"Tian J, Zhang M, Suo M, Liu D, Wang X, Liu M, Pan J, Jin T, An F (2021) Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats. J Cell Mol Med 25:7642\u20137659. https:\/\/doi.org\/10.1111\/jcmm.16601","journal-title":"J Cell Mol Med"},{"key":"10093_CR37","doi-asserted-by":"publisher","DOI":"10.2337\/dbi20-0040","author":"KR Tuttle","year":"2021","unstructured":"Tuttle KR, Brosius FC, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, Manley T, Mcguire DK, Molitch ME, Mottl AK, Perreault L, Rosas SE, Rossing P, Sola L, Vallon V, Wanner C, Perkovic V (2021) SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the national kidney foundation. Diabetes. https:\/\/doi.org\/10.2337\/dbi20-0040","journal-title":"Diabetes"},{"key":"10093_CR38","doi-asserted-by":"publisher","first-page":"41166","DOI":"10.1038\/srep41166","volume":"7","author":"A Van Steenbergen","year":"2017","unstructured":"Van Steenbergen A, Balteau M, Ginion A, Fert\u00e9 L, Battault S, Ravenstein CDMD, Balligand J-L, Daskalopoulos E-P, Gilon P, Despa F, Despa S, Vanoverschelde J-L, Horman S, Koepsell H, Berry G, Hue L, Bertrand L, Beauloye C (2017) Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep 7:41166. https:\/\/doi.org\/10.1038\/srep41166","journal-title":"Sci Rep"},{"key":"10093_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1440-1797.2005.00334.x","volume":"10","author":"W Wang","year":"2005","unstructured":"Wang W, Koka V, Lan HY (2005) Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (carlton) 10:48\u201356","journal-title":"Nephrology (carlton)"},{"key":"10093_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s40001-022-00945-z","volume":"27","author":"Y Wang","year":"2022","unstructured":"Wang Y, Gao T, Meng C, Li S, Bi L, Geng Y, Zhang P (2022) Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. Eur J Med Res 27:314. https:\/\/doi.org\/10.1186\/s40001-022-00945-z","journal-title":"Eur J Med Res"},{"key":"10093_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","volume":"32","author":"Y Ye","year":"2018","unstructured":"Ye Y, Jia X, Bajaj M, Birnbaum Y (2018) Dapagliflozin attenuates Na+\/H+ exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther 32:553\u2013558. https:\/\/doi.org\/10.1007\/s10557-018-6837-3","journal-title":"Cardiovasc Drugs Ther"},{"key":"10093_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J (2018) Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 15:335\u2013346. https:\/\/doi.org\/10.1016\/j.redox.2017.12.019","journal-title":"Redox Biol"}],"container-title":["Biogerontology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10522-024-10093-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10522-024-10093-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10522-024-10093-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T06:30:34Z","timestamp":1717137034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10522-024-10093-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10093"],"URL":"https:\/\/doi.org\/10.1007\/s10522-024-10093-y","relation":{},"ISSN":["1389-5729","1573-6768"],"issn-type":[{"value":"1389-5729","type":"print"},{"value":"1573-6768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}